

Hugues de Thé

Chaire Oncologie cellulaire et moléculaire (2014-)

BIBLIOGRAPHIE

PRINCIPALES PUBLICATIONS (1987-2025)

- de The, H., A. Marchio, P. Tiollais, and A. Dejean, *A novel steroid thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma*. **Nature**, 1987. 330(6149): p. 667-70.
- Brand, N., M. Petkovich, A. Krust, P. Chambon, H. de The, A. Marchio, P. Tiollais, and A. Dejean, *Identification of a second human retinoic acid receptor*. **Nature**, 1988. 332(6167): p. 850-3.
- de The, H., A. Marchio, P. Tiollais, and A. Dejean, *Differential expression and ligand regulation of the retinoic acid receptor alpha and beta genes*. **The EMBO journal**, 1989. 8(2): p. 429-33.
- Chomienne, C., P. Ballerini, M. Balitrand, M. Huang, I. Krawice, S. Castaigne, P. Fenaux, P. Tiollais, A. Dejean, L. Degos, and H. de Thé, *The retinoic acid receptor is rearranged in retinoic acid sensitive promyelocytic leukemias*. **Leukemia**, 1990. 4: p. 802-807.
- de The, H., C. Chomienne, M. Lanotte, L. Degos, and A. Dejean, *The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus*. **Nature**, 1990. 347(6293): p. 558-61.
- de Thé, H., M.d.M. Vivanco-Ruiz, P. Tiollais, H. Stunnenberg, and A. Dejean, *Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene*. **Nature**, 1990. 343: p. 177-180.
- de Thé, H., C. Lavau, A. Marchio, C. Chomienne, L. Degos, and A. Dejean, *The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR*. **Cell**, 1991. 66(4): p. 675-84.
- Daniel, M.-T., M. Koken, O. Romagné, S. Barbey, A. Bazarbachi, M. Stadler, M.-C. Guillemain, L. Degos, C. Chomienne, and H. de Thé, *PML protein expression in hematopoietic and acute promyelocytic leukemia cells*. **Blood**, 1993. 82: p. 1858-1867.
- Warrell, R., H. de Thé, Z. Wang, and L. Degos, *Acute promyelocytic leukemia*. **New Engl. J. Med.**, 1993. 329: p. 177-189.
- Koken, M.H.M., F. Puvion-Dutilleul, M.C. Guillemain, A. Viron, G. Linares-Cruz, N. Stuurman, L. de Jong, C. Szosteki, F. Calvo, C. Chomienne, L. Degos, E. Puvion, and H. de Thé, *The t(15;17) translocation alters a nuclear body in a RA-reversible fashion*. **EMBO J.**, 1994. 13: p. 1073-1083.

- Stadler, M., M.K. Chelbi-Alix, M.H.M. Koken, L. Venturini, C. Lee, A. Saïb, F. Quignon, L. Pelicano, M.-C. Guillemain, C. Schindler, and H. de Thé, *Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element*. **Oncogene**, 1995. 11: p. 2565-2573.
- André, C., M.-C. Guillemain, J. Zhu, M.H.M. Koken, F. Quignon, L. Hervé, M.K. Chelbi-Alix, D. Dhumeaux, Z.Y. Wang, L. Degos, Z. Chen, and H. de Thé, *The PML and PML/RAR- α domains. From autoimmunity to molecular oncology and from retinoic acid to arsenic*. **Exp. Cell Res.**, 1996. 229: p. 253-260.
- Chen, G.Q., X.G. Shi, W. Tang, S.M. Xiong, J. Zhu, X. Cai, Z.G. Han, J.H. Ni, G.Y. Shi, P.M. Jia, M.M. Liu, K.L. He, C. Niu, J. Ma, P. Zhang, T.D. Zhang, P. Paul, T. Naoe, K. Kitamura, W. Miller, S. Waxman, Z.Y. Wang, H. de The, S.J. Chen, and Z. Chen, *Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): I. As₂O₃ exerts dose-dependent dual effects on APL cells*. **Blood**, 1997. 89(9): p. 3345-53.
- Quignon, F., Z. Chen, and H. de Thé, *Retinoic acid and arsenic: towards oncogene targeted treatments of acute promyelocytic leukaemia*. **Biochim. Biophys. Acta**, 1997. 1333: p. M53-M61.
- Zhu, J., M.H.M. Koken, F. Quignon, M.K. Chelbi-Alix, L. Degos, Z.Y. Wang, Z. Chen, and H. de The, *Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia*. **Proc. Natl. Acad. Sci. USA**, 1997. 94: p. 3978-3983.
- Quignon, F., F. de Bels, M. Koken, J. Feunteun, J.-C. Ameisen, and H. de Thé, *PML induces a caspase-independent cell death process*. **Nature Genet.**, 1998. 20: p. 259-265.
- Koken, M.H.M., M.-T. Daniel, M. Gianni, A. Zelent, J. Licht, A. Buzyn, P. Minard, L. Degos, B. Varet, and H. de The, *Retinoic acid, but not arsenic trioxide, degrades the PLZF/RAR α fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient*. **Oncogene**, 1999. 18: p. 1113-1118.
- Lallemand-Breitenbach, V., M.-C. Guillemain, A. Janin, M.-T. Daniel, L. Degos, S.C. Kogan, J.M. Bishop, and H. de The, *Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia*. **J. Exp. Med.**, 1999. 189: p. 1043-1052.
- Venturini, L., J. You, M. Stadler, R. Galien, V. Lallemand, M.H.M. Koken, M.G. Mattei, A. Ganser, P. Chambon, R. Losson, and H. de The, *TIF1 γ , a novel member of the transcriptional intermediary factor 1 family*. **Oncogene**, 1999. 18: p. 1209-1217.
- Zhu, J., M. Gianni, E. Kopf, N. Honore, M. Chelbi-Alix, M. Koken, F. Quignon, C. Rochette-Egly, and H. de The, *Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor α (RAR α) and oncogenic RAR α fusion proteins*. **Proc. Natl. Acad. Sci. USA**, 1999. 96: p. 14807-14812.
- Lallemand-Breitenbach, V., J. Zhu, F. Puvion, M. Koken, N. Honore, A. Doubeikovsky, E. Duprez, P.P. Pandolfi, E. Puvion, P. Freemont, and H. de The, *Role of Promyelocytic Leukemia (PML) Sumolation in Nuclear Body Formation, 11S Proteasome Recruitment, and As(2)O(3)-induced PML or PML/Retinoic Acid Receptor α Degradation*. **J Exp Med**, 2001. 193(12): p. 1361-72.
- Bertheau, P., F. Plassa, M. Espie, E. Turpin, A. de Roquancourt, M. Marty, F. Lerebours, Y. Beuzard, A. Janin, and H. de The, *Effect of mutated TP53 on response of advanced breast cancers to high- dose chemotherapy*. **Lancet**, 2002. 360(9336): p. 852-4.
- Guillemain, M.C., E. Raffoux, D. Vitoux, S. Kogan, H. Soilihi, V. Lallemand-Breitenbach, J. Zhu, A. Janin, M.T. Daniel, B. Gourmel, L. Degos, H. Dombret, M. Lanotte, and H. De The, *In Vivo Activation of cAMP Signaling Induces Growth Arrest and Differentiation in Acute Promyelocytic Leukemia*. **J Exp Med**, 2002. 196(10): p. 1373-1380.

- Zhu, J., Z. Chen, V. Lallemand-Breitenbach, and H. de Thé, *How acute promyelocytic leukemia revived arsenic*. **Nature Reviews on Cancer**, 2002. 2: p. 705-713.
- Kamashev, D.E., D. Vitoux, and H. De Thé, *PML/RARA-RXR oligomers mediate retinoid- and rexinoid- /cAMP in APL cell differentiation*. **J. Exp. Med.**, 2004. 199: p. 1-13.
- Lallemand-Breitenbach, V., J. Zhu, S. Kogan, Z. Chen, and H. de The, *Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia*. **Nat Rev Cancer**, 2005. 5(10): p. 821-7.
- Zhu, J., J. Zhou, L. Peres, F. Riaucoux, N. Honore, S. Kogan, and H. de The, *A sumoylation site in PML/RARA is essential for leukemic transformation*. **Cancer Cell**, 2005. 7(2): p. 143-53.
- Condemine, W., Y. Takahashi, J. Zhu, F. Puvion-Dutilleul, S. Guegan, A. Janin, and H. de The, *Characterization of endogenous human promyelocytic leukemia isoforms*. **Cancer Res**, 2006. 66(12): p. 6192-8.
- Bertheau, P., E. Turpin, D.S. Rickman, M. Espie, A. de Reynies, J.P. Feugeas, L.F. Plassa, H. Soliman, M. Varna, A. de Roquancourt, J. Lehmann-Che, Y. Beuzard, M. Marty, J.L. Misset, A. Janin, and H. de The, *Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen*. **PLoS medicine**, 2007. 4(3): p. e90.
- Condemine, W., Y. Takahashi, M. Le Bras, and H. de The, *A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells*. **J. Cell Sci.**, 2007. 120.
- Medyouf, H., H. Alcalde, C. Berthier, M.C. Guillemin, N.R. dos Santos, A. Janin, D. Decaudin, H. de The, and J. Ghysdael, *Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia*. **Nature medicine**, 2007. 13(6): p. 736-41.
- Zhu, J., R. Nasr, L. Peres, F. Riaucoux-Lormiere, N. Honore, C. Berthier, D. Kamashev, J. Zhou, D. Vitoux, C. Lavau, and H.s. de The, *RXR is an essential component of the oncogenic PML/RARA complex in vivo*. **Cancer Cell**, 2007. 12(1): p. 23-35.
- Lallemand-Breitenbach, V., M. Jeanne, S. Benhenda, R. Nasr, M. Lei, L. Peres, J. Zhou, J. Zhu, B. Raught, and H. de The, *Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway*. **Nat Cell Biol**, 2008. 10(5): p. 547-55.
- Nasr, R., M.C. Guillemin, O. Ferhi, H. Soilihi, L. Peres, C. Berthier, P. Rousselot, M. Robledo-Sarmiento, V. Lallemand-Breitenbach, B. Gourmel, D. Vitoux, P.P. Pandolfi, C. Rochette-Egly, J. Zhu, and H. de The, *Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation*. **Nat Med**, 2008. 14(12): p. 1333-42.
- de The, H. and Z. Chen, *Acute promyelocytic leukaemia: novel insights into the mechanisms of cure*. **Nat Rev Cancer**, 2010. 10(11): p. 775-83.
- El Hajj, H., M. El-Sabban, H. Hasegawa, G. Zaatari, J. Ablain, S.T. Saab, A. Janin, R. Mahfouz, R. Nasr, Y. Kfoury, C. Nicot, O. Hermine, W. Hall, H. de The, and A. Bazarbachi, *Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia*. **J Exp Med**, 2010. 207(13): p. 2785-92.
- Jeanne, M., V. Lallemand-Breitenbach, O. Ferhi, M. Koken, M. Le Bras, S. Duffort, L. Peres, C. Berthier, H. Soilihi, B. Raught, and H. de The, *PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3*. **Cancer Cell**, 2010. 18(1): p. 88-98.
- Lallemand-Breitenbach, V. and H. de The, *PML nuclear bodies*. **Cold Spring Harb Perspect Biol.** , 2010. 2: p. a000661.
- Zhang, X.W., X.J. Yan, Z.R. Zhou, F.F. Yang, Z.Y. Wu, H.B. Sun, W.X. Liang, A.X. Song, V. Lallemand-Breitenbach, M. Jeanne, Q.Y. Zhang, H.Y. Yang, Q.H. Huang, G.B. Zhou,

- J.H. Tong, Y. Zhang, J.H. Wu, H.Y. Hu, H. de The, S.J. Chen, and Z. Chen, *Arsenic trioxide controls the fate of the PML-RAR α oncoprotein by directly binding PML*. **Science**, 2010. 328(5975): p. 240-3.
- Ablain, J. and H. de The, *Revisiting the differentiation paradigm in acute promyelocytic leukemia*. **Blood**, 2011. 117(22): p. 5795-802.
 - Ablain, J., R. Nasr, A. Bazarbachi, and H. de The, *Oncoprotein proteolysis, an unexpected Achilles' Heel of cancer cells?*. **Cancer Discovery**, 2011. 1: p. 117-127.
 - Chen, S.J., G.B. Zhou, X.W. Zhang, J.H. Mao, H. de The, and Z. Chen, *From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia*. **Blood**, 2011. 117(24): p. 6425-37.
 - de The, H., M. Le Bras, and V. Lallemand-Breitenbach, *The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies*. **The Journal of cell biology**, 2012. 198(1): p. 11-21.
 - Lallemand-Breitenbach, V. and H. de The, *Hematopoietic cells burn fat to prevent exhaustion*. **Cell stem cell**, 2012. 11('): p. 447-449.
 - Lallemand-Breitenbach, V., J. Zhu, Z. Chen, and H. de The, *Mechanisms of APL cure through PML/RARA degradation by As₂O₃*. **Trends in Molecular Medicine**, 2012. 18: p. 36-42.
 - Ablain, J., M. Leiva, L. Peres, J. Fonsart, E. Anthony, and H. de The, *Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies*. **The Journal of experimental medicine**, 2013. 210(4): p. 647-53.
 - Ablain, J., K. Rice, H. Soilihi, A. de Reynies, S. Minucci, and H. de The, *Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure*. **Nature medicine**, 2014. 20: p. 167-74.
 - Lehmann-Che, J., C. Bally, and H. de The, *therapy resistance in APL*. **New Engl. J. Med.**, 2014. 371: p. 1171-1172.
 - Sahin, U., O. Ferhi, X. Carnec, A. Zamborlini, L. Peres, F. Jollivet, A. Vitaliano-Prunier, H. de The, and V. Lallemand-Breitenbach, *Interferon controls SUMO availability via the Lin28 and let-7 axis to impede virus replication*. **Nature communications**, 2014. 19: p. 4187.
 - Sahin, U., O. Ferhi, M. Jeanne, S. Benhenda, C. Berthier, F. Jollivet, M. Niwa-Kawakita, O. Faklaris, N. Setterblad, H. de The, and V. Lallemand-Breitenbach, *Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins*. **The Journal of cell biology**, 2014. 204(6): p. 931-45.
 - Vitaliano-Prunier, A., J. Halftermeyer, J. Ablain, A. de Reynies, L. Peres, M. Le Bras, D. Metzger, and H. de The, *Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation*. **Blood**, 2014. 124(25): p. 3772-80.
 - Ablain, J., B. Poirot, C. Esnault, J. Lehmann-Che, and H. de The, *p53 as an Effector or Inhibitor of Therapy Response*. **Cold Spring Harb Perspect Med**, 2015. 6(1): p. a026260.
 - El Hajj, H., Z. Dassouki, C. Berthier, E. Raffoux, L. Ades, O. Legrand, R. Hleihel, U. Sahin, N. Tawil, A. Salameh, K. Zibara, N. Darwiche, M. Mohty, H. Dombret, P. Fenaux, H. de The, and A. Bazarbachi, *Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells*. **Blood**, 2015. 125(22): p. 3447-54.
 - Ivanschitz, L., Y. Takahashi, F. Jollivet, O. Ayrault, M. Le Bras, and H. de The, *PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence*. **Proc Natl Acad Sci U S A**, 2015. 112(46): p. 14278-83.

- Ferhi, O., L. Peres, S. Tessier, H. de The, and V. Lallemand-Breitenbach, *Comment on "SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML"*. **Sci Signal**, 2016. 9(440): p. tc1.
- de The, H., P.P. Pandolfi, and Z. Chen, *Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure*. **Cancer Cell**, 2017. 32(5): p. 552-560.
- Niwa-Kawakita, M., O. Ferhi, H. Soilihi, M. Le Bras, V. Lallemand-Breitenbach, and H. de The, *PML is a ROS sensor activating p53 upon oxidative stress*. **J Exp Med**, 2017. 214(11): p. 3197-3206.
- de The, H., *Differentiation therapy revisited*. **Nat Rev Cancer**, 2018. 18(2): p. 117-127.
- Gachet, S., T. El-Chaar, D. Avran, E. Genesca, F. Catez, S. Quentin, M. Delord, G. Therizols, D. Briot, G. Meunier, L. Hernandez, M. Pla, W.K. Smits, J. Buijs-Gladdines, W. Van Looke, G. Menschaert, I. Andre-Schmutz, T. Taghon, P. Van Vlierberghe, J.P. Meijerink, A. Baruchel, H. Dombret, E. Clappier, J.J. Diaz, C. Gazin, H. de The, F. Sigaux, and J. Soulier, *Deletion 6q drives T-cell leukemia progression by ribosome modulation*. **Cancer Discov**, 2018.
- Lallemand-Breitenbach, V. and H. de The, *PML nuclear bodies: from architecture to function*. **Curr Opin Cell Biol**, 2018. 52: p. 154-161.
- Lehmann-Che, J., C. Bally, E. Letouze, C. Berthier, H. Yuan, F. Jollivet, L. Ades, B. Cassinat, P. Hirsch, A. Pigneux, M.J. Mozziconacci, S. Kogan, P. Fenaux, and H. de The, *Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia*. **Nat Commun**, 2018. 9(1): p. 2047.
- Wang, P., S. Benhenda, H. Wu, V. Lallemand-Breitenbach, T. Zhen, F. Jollivet, L. Peres, Y. Li, S.J. Chen, Z. Chen, H. de The, and G. Meng, *RING tetramerization is required for nuclear body biogenesis and PML sumoylation*. **Nat Commun**, 2018. 9(1): p. 1277.
- Esnault, C., R. Rahme, K.L. Rice, C. Berthier, C. Gaillard, S. Quentin, A.L. Maubert, S. Kogan, and H. de The, *FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias*. **Blood**, 2019. 133(13): p. 1495-1506.
- Dagher, T., N. Maslah, V. Edmond, B. Cassinat, W. Vainchenker, S. Giraudier, F. Pasquier, E. Verger, M. Niwa-Kawakita, V. Lallemand-Breitenbach, I. Plo, J.J. Kiladjian, J.L. Villeval, and H. de The, *JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML*. **J Exp Med**, 2021. 218(2).
- Geoffroy, M.C., c. Esnault, and H. de The, *Retinoids in haematology, a timely revival ?*. **Blood**, 2021. 137(18): p. 2429-2437.
- Gionfriddo, I., L. Brunetti, F. Mezzasoma, F. Milano, V. Cardinali, R. Ranieri, A. Venanzi, S. Pierangeli, C. Vetro, G. Spinozzi, E. Dorillo, H.C. Wu, C. Berthier, R. Ciurnelli, M.J. Griffin, C.E. Jennings, E. Tiacci, P. Sportoletti, F. Falzetti, H. de The, G.J. Veal, M.P. Martelli, and B. Falini, *Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML*. **Leukemia**, 2021.
- Wu, H.C., D. Rerolle, C. Berthier, R. Hleihel, T. Sakamoto, S. Quentin, S. Benhenda, C. Morganti, C.C. Wu, L. Conte, S. Rimsky, M. Sebert, E. Clappier, S. Souquere, S. Gachet, J. Soulier, S. Durand, J.J. Trowbridge, P. Benit, P. Rustin, H. El Hajj, E. Raffoux, L. Ades, R. Itzykson, H. Dombret, P. Fenaux, O. Espeli, G. Kroemer, L. Brunetti, T.W. Mak, V. Lallemand-Breitenbach, A. Bazarbachi, B. Falini, M.F. Martelli, and H. de The, *Actinomycin D targets NPM1c-primed mitochondria to restore PML- driven senescence in AML therapy*. **Cancer Discov**, 2021. 11(12): p. 3198-3213.
- Tessier, S., O. Ferhi, M.C. Geoffroy, R. Gonzalez-Prieto, A. Canat, S. Quentin, M. Pla, M. Niwa-Kawakita, P. Bercier, D. Rerolle, M. Tirard, P. Therizols, E. Fabre, A.C.O. Vertegaal, H. de The, and V. Lallemand-Breitenbach, *Exploration of nuclear body-enhanced*

sumoylation reveals that PML represses 2-cell features of embryonic stem cells. **Nat Commun**, 2022. 13(1): p. 5726.

- Bercier, P., Q.Q. Wang, N. Zang, J. Zhang, C. Yang, Y. Maimaitiyiming, M. Abou-Ghali, C. Berthier, C. Wu, M. Niwa-Kawakita, T. Dirami, M.C. Geoffroy, O. Ferhi, S. Quentin, S. Benhenda, Y. Ogra, Z. Gueroui, C. Zhou, H. Naranmandura, H. de Thé, and V. Lallemand-Breitenbach, *Structural basis of PML/RARA oncoprotein targeting by arsenic unravels a cysteine rheostat controlling PML body assembly and function.* **Cancer Discov**, 2023. Online.
- Rerolle, D. and H. de Thé, *The PML hub: An emerging actor of leukemia therapies.* **J Exp Med**, 2023. 220(8).
- Rérolle D, Wu HC, de Thé H. *Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities.* **Cold Spring Harb Perspect Med**. 2024. 14(9):a041582.
- Letai, A and de Thé, H *Conventional chemotherapy: millions of cures, unresolved therapeutic index.* **Nat Rev Cancer** 2025. (3):209-218